Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

🏛️ Moderna agreed to pay up to $2.25 billion in settlement fees over patent infringement claims with Arbutus Biopharma and Genevant Sciences.

💸 The company will make an initial payment of $950 million, making this one of the largest patent settlements in biotech history.

🛑 Earlier last month, the FDA initially refused to review Moderna’s flu vaccine application for older adults due to cited safety concerns.

🔄 That regulatory stance has since reversed, with the FDA agreeing to review the mRNA flu vaccine after all.

📈 Despite these setbacks, Moderna’s stock rose over 7% following news of the patent settlement resolution.

🧬 CEO Stéphane Bancel stated that resolving the legacy pandemic matter removes uncertainty and allows focus on future growth.

🎯 Analysts suggest Moderna must diversify away from vaccines into oncology to achieve stability and break even.

💊 The company is partnering with Merck to develop mRNA cancer therapies for melanoma, lung, kidney, and bladder cancer.

⚖️ Federal funding for mRNA vaccine research was cut by HHS Secretary Robert F. Kennedy Jr., but experts view the risk differently for oncology treatments.

🎨 Moderna is shifting its primary revenue driver toward oncology, transforming from a vaccine company to a therapeutics powerhouse.

🔬 Recent Phase 3 trial results show promising efficacy for an mRNA vaccine combined with Merck’s Keytruda in treating high-risk melanoma.

🤝 A senior FDA official noted that while infectious disease applications haven't pan out yet, oncology benefits are still highly anticipated.

💰 Analysts emphasize that cancer vaccines are the main catalyst for investor optimism regarding Moderna's turnaround potential.

⚠️ However, some experts remain skeptical about whether Moderna will successfully execute this strategic pivot and achieve profitability.

Bullish Signals
  • Moderna's stock price rallied significantly, rising over 7% following news of the settlement agreement with Arbutus Biopharma Corp. and Genevant Sciences GmbH.
  • The FDA reversed its initial decision to refuse review and agreed to evaluate Moderna's application for its messenger RNA flu vaccine after all.
  • Moderna has secured a strong strategic partnership with Merck, establishing a shared revenue opportunity in oncology that could help the company break even.
  • Promising Phase 3 clinical trial results were recently announced for Moderna's mRNA cancer vaccine combined with Merck's drug Keytruda for treating high-risk melanoma.
  • Management and cofounders, including CEO Stéphane Bancel and Robert Langer, expressed optimism about transitioning from a COVID-focused company to one driven by oncology and other indications.
  • Moderna has diversified its pipeline into new areas such as norovirus vaccines and various cancer types including lung, kidney, and bladder cancers, reducing reliance on infectious disease mandates.
  • Investors remain engaged due to the potential for Moderna's 'Hollywood-style redemption arc' driven by its cancer vaccine business and oncology platform benefits.
Risk Factors
  • Moderna faces a potential settlement liability of up to $2.25 billion for patent infringement claims, representing one of the largest such deals in history.
  • The FDA initially refused to review Moderna's application for its messenger RNA flu vaccine for older adults due to methodological and safety concerns regarding trial design.
  • Federal health officials, led by HHS Secretary Robert F. Kennedy Jr., have publicly stated they would no longer fund mRNA vaccine work due to opposition to vaccines.
  • Moderna has announced it will stop investing in late-stage vaccine trials because of growing opposition to vaccines, potentially stalling its infectious disease portfolio.
  • Moderna has a long history of burning cash, raising concerns about its liquidity and ability to sustain operations through current challenges.
  • While some officials note mRNA platform benefits outside infectious diseases have not yet panned out as hoped, this suggests delays or lack of progress in diversifying beyond vaccines.
  • Analysts express uncertainty regarding whether Moderna can successfully execute a turnaround without cancer oncology being the primary revenue driver.
Full Analysis
Moderna faces significant financial and regulatory challenges in early 2026 but has secured several strategic wins that could stabilize its future. The company announced it will pay up to $2.25 billion to resolve patent infringement claims with Arbutus Biopharma Corp. and Genevant Sciences GmbH regarding its development of the COVID-19 vaccine, which would be one of the largest patent settlements in history if fully paid. Shortly after this announcement, the FDA reversed a prior decision refusing to review Moderna's flu vaccine for older adults, instead agreeing to evaluate it after addressing initial methodological and safety concerns raised by the agency. To offset these costs and regulatory hurdles, Moderna is aggressively pivoting its strategy toward oncology treatments and rare diseases rather than relying on legacy COVID products or purely infectious disease vaccines that face political scrutiny. The company is collaborating with Merck on cancer vaccines, notably for high-risk melanoma combined with Keytruda, with Phase 3 trial results expected later in the year. Analysts from William Blair and Leerink Partners suggest this diversification could transform Moderna into a revenue-driven oncology company, potentially breaking even despite federal opposition to mRNA technology led by Health and Human Services Secretary Robert F. Kennedy Jr. Despite concerns about cash burn and political hostility toward vaccines from the Trump administration, insiders like co-founder Robert Langer express optimism that the company can navigate this transition. The potential success of its melanoma vaccine and other cancer pipeline targets for lung, kidney, and bladder cancers provides a path toward financial stability. However, experts caution that while infectious disease vaccines may still face political headwinds, the oncology sector represents the critical driver for Moderna's future growth and investor confidence, with cost-sharing arrangements with Merck helping to manage the substantial costs of pivotal studies.